Analysts Offer Insights on Healthcare Companies: BioMarin (BMRN) and Trillium Therapeutics (TRIL)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin (BMRN) and Trillium Therapeutics (TRIL) with bullish sentiments.

BioMarin (BMRN)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on BioMarin, with a price target of $127. The company’s shares opened today at $94.02.

According to TipRanks.com, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.8% and a 33.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Liquidia Technologies Inc.

BioMarin has an analyst consensus of Strong Buy, with a price target consensus of $123, a 30.8% upside from current levels. In a report issued on October 31, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $126 price target.

.

See today’s analyst top recommended stocks >>

Trillium Therapeutics (TRIL)

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Trillium Therapeutics today. The company’s shares opened today at $2.62, close to its 52-week low of $2.28.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 6.1% and a 40.9% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Trillium Therapeutics.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts